CASTLE primary efficacy endpoint at week 96: HIV RNA <50 c/mL (ITT-CVR NC=F)

Primary efficacy
Supporting analyses:
ITT-TLOVR: HIV RNA <50 c/mL: ATV/r 70%, LPV/r 63%; 6.6 (0.4, 12.7)
OT-VROC: HIV RNA <50 c/mL: ATV/r 89%, LPV/r 88%; 1.6 (-3.1, 6.2)

Adapted from Molina J-M et al. ICAAC/IDSA, Washington, USA, 2008, Poster H-1250d